Evaluation of Toxicological Data on Experior

To support the evaluation of a new veterinary pharmaceutical product intended for use in bovines, a scientific review was requested of submitted toxicological data related to the active compound LY488756. This compound, proposed under the product name Experior, had been advanced for registration based on its claimed selective action on β3-adrenergic receptors and a lack of mutagenic, carcinogenic, or teratogenic effects. Given its potential entry into the human food supply via meat residues, an independent expert analysis of the submission was deemed necessary to determine its safety.

The scope of the review included an in-depth assessment of both summary and raw toxicological data—approximately 1,800 and 10,000 pages respectively—as well as additional supporting materials provided during the course of the review. The work involved evaluating the design, analytical methods, and reported outcomes of studies conducted in multiple species including humans. A key focus was determining whether the data were adequate to derive a scientifically sound acceptable daily intake (ADI) and to establish a relevant no-observed-adverse-effect level (NOAEL).

Further responsibilities included identifying any gaps in the data, providing recommendations for additional data requirements where needed, and proposing viable alternatives where information was incomplete. The work concluded with the development of a detailed review report following a format specified by the requesting authority, including administrative documentation, scientific evaluations, and final recommendations on human food and occupational safety associated with LY488756 use in feedlot cattle.